口服司美格鲁肽对阿尔茨海默病无疗效!面对AD研发黑洞,恒瑞、康方等仍入局

时代周报
Nov 26

本文来源:时代周报 作者:林昀肖11月24日,诺和诺德公布口服司美格鲁肽针对早期症状性阿尔茨海默病(AD)的III期evoke和evoke+临床试验的两年期主要分析结果。evoke和evoke+试验未能证实司美格鲁肽在减缓阿尔茨海默病进展方面优于安慰剂,该评估主要基于临床痴呆评定量表-总和评分相对于基线的变化。尽管在这两项试验中,司美格鲁肽治疗改善了阿尔茨海默病相关生物标志物,但这并未转化为疾病...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10